Victory Capital Management
CCCC icon

Victory Capital Management’s C4 Therapeutics CCCC Stock Holding History

Victory Capital Management’s Portfolio CCCC Stock Details CCCC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$54.1K Buy
+11,582
New +$39.6K ﹤0.01% 2391
2022
Q2 		– Sell
-16,409
Closed -$141K – 2707
2022
Q1 		$141K Sell
16,409
-121
-0.7% -$2.94K ﹤0.01% 2466
2021
Q4 		$532K Buy
16,530
+6,387
+63% +$253K ﹤0.01% 2116
2021
Q3 		$453K Buy
10,143
+838
+9% +$35.9K ﹤0.01% 2218
2021
Q2 		$352K Buy
9,305
+947
+11% +$33.9K ﹤0.01% 2360
2021
Q1 		$309K Buy
+8,358
New +$332K ﹤0.01% 2383

Other funds holding CCCC

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $322M AUM
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Victory Capital Management's CCCC Position: Q2 2026 in Review

Victory Capital Management opened a new position in C4 Therapeutics (CCCC) in Q2 2026: 11,582 shares worth $54.1K. The stake represents ﹤0.01% of the portfolio and ranks #2391 among its holdings. This is a return to the name: Victory Capital Management previously reported a position in CCCC as recently as Q1 2022.

Victory Capital Management first reported a position in CCCC in Q1 2021 and has held it in 6 quarters since. The position peaked at $532K in Q4 2021. 147 funds tracked by Wall St. Rank hold CCCC as of Q2 2026.

  • Victory Capital Management held 11,582 shares of C4 Therapeutics worth $54.1K as of Q2 2026.
  • C4 Therapeutics was a new Victory Capital Management position in Q2 2026.
  • C4 Therapeutics made up ﹤0.01% of Victory Capital Management's portfolio in Q2 2026, its #2391 holding.
  • Victory Capital Management first reported a position in C4 Therapeutics in Q1 2021 and has held it in 6 quarters since.
  • Victory Capital Management's C4 Therapeutics position peaked at $532K in Q4 2021.
  • 147 funds tracked by Wall St. Rank held C4 Therapeutics as of Q2 2026.

Based on Victory Capital Management's 13F filing for Q2 2026, filed 7 Aug 2026.